InnoCare Pharma Ltd. (INCPF)
OTHER OTC:INCPF
INCPF Stock Chart & Stats
$1.55
--
Market closed
$1.55
--
Day’s Range― - ―
52-Week Range$1.55 - $3.26
Previous CloseN/A
VolumeN/A
Average Volume (3M)6.00
Market Cap
$2.07B
Enterprise Value$8.96B
Total Cash (Recent Filing)$7.07B
Total Debt (Recent Filing)$1.80B
Price to Earnings (P/E)23.5
Beta0.18
Next Earnings
Aug 25, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.40
Shares Outstanding1,496,284,200
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.52
Price to Sales (P/S)8.47
P/FCF Ratio148.84
Enterprise Value/Market Cap4.33
Enterprise Value/Revenue3.59
Enterprise Value/Gross Profit3.97
Enterprise Value/Ebitda13.35
Forecast
1Y Price Target
$2.43Price Target Upside56.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.01
Revenue Forecast (FY)$290.84M
Bulls Say, Bears Say
Bulls Say
High Margins & ProfitabilityThe company shows a durable profitability inflection with exceptionally high gross margins and healthy operating and net margins. Such margin structure indicates product pricing power and operational leverage, supporting reinvestment in R&D and commercialization over the medium term.
Controlled Leverage And Equity BaseA low D/E ratio and a sizable equity base provide financial flexibility to fund clinical programs, absorb setbacks, or pursue partnerships. Manageable leverage reduces solvency risk and supports multi-quarter investment plans without forcing near-term dilutive financing.
In-house R&D And Commercialization FocusOwning both R&D and commercialization capabilities creates durable competitive advantages: faster feedback loops, greater control of go-to-market, and potential margin capture on approved products. Focused therapeutic expertise supports sustained pipeline relevance.
Bears Say
Weakened Cash ConversionDespite accounting profitability, cash generation has materially weakened versus prior year, with FCF down ~60%. This gap between earnings and cash curtails internal funding for trials and commercialization, increasing reliance on external capital and elevating execution risk over several quarters.
Uneven Revenue GrowthTop-line momentum remains inconsistent, moving from low or volatile growth to modest TTM gains. Without steadier revenue expansion, sustaining R&D scale, fixed-cost absorption, and long-term margin improvements will hinge on execution and new product traction, posing a structural growth risk.
Declining Assets And Equity Vs Prior YearA contraction in assets and equity relative to the prior year reduces the balance-sheet buffer and may limit capacity for near-term investments or absorb unexpected costs. If persistent, this trend could restrict strategic flexibility and increase funding sensitivity.
InnoCare Pharma Ltd. News
INCPF FAQ
What was InnoCare Pharma Ltd.’s price range in the past 12 months?
InnoCare Pharma Ltd. lowest stock price was $1.55 and its highest was $3.26 in the past 12 months.
What is InnoCare Pharma Ltd.’s market cap?
InnoCare Pharma Ltd.’s market cap is $2.07B.
When is InnoCare Pharma Ltd.’s upcoming earnings report date?
InnoCare Pharma Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 59 days.
How were InnoCare Pharma Ltd.’s earnings last quarter?
InnoCare Pharma Ltd. released its earnings results on Apr 23, 2026. The company reported $0.009 earnings per share for the quarter, beating the consensus estimate of N/A by $0.009.
Is InnoCare Pharma Ltd. overvalued?
According to Wall Street analysts InnoCare Pharma Ltd.’s price is currently Undervalued.
Does InnoCare Pharma Ltd. pay dividends?
InnoCare Pharma Ltd. does not currently pay dividends.
What is InnoCare Pharma Ltd.’s EPS estimate?
InnoCare Pharma Ltd.’s EPS estimate is 0.01.
How many shares outstanding does InnoCare Pharma Ltd. have?
InnoCare Pharma Ltd. has 1,496,284,200 shares outstanding.
What happened to InnoCare Pharma Ltd.’s price movement after its last earnings report?
InnoCare Pharma Ltd. reported an EPS of $0.009 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of InnoCare Pharma Ltd.?
Currently, no hedge funds are holding shares in INCPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InnoCare Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.61%
12-Months-Change
Fundamentals
Return on Equity
10.12%
Trailing 12-Months
Asset Growth
16.67%
Trailing 12-Months
Company Description
InnoCare Pharma Ltd.
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.
INCPF Stock 12 Month Forecast
Average Price Target
$2.43
▲(56.63% Upside)
Zai Lab Ltd
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Ownership Overview
―
Insiders
3.11% Mutual Funds
― Other Institutional Investors
93.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---